ES3038949T3 - Compounds for use in the treatment of attention deficit hyperactivity disorder - Google Patents

Compounds for use in the treatment of attention deficit hyperactivity disorder

Info

Publication number
ES3038949T3
ES3038949T3 ES22708379T ES22708379T ES3038949T3 ES 3038949 T3 ES3038949 T3 ES 3038949T3 ES 22708379 T ES22708379 T ES 22708379T ES 22708379 T ES22708379 T ES 22708379T ES 3038949 T3 ES3038949 T3 ES 3038949T3
Authority
ES
Spain
Prior art keywords
compound
adhd
use according
formula
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22708379T
Other languages
English (en)
Spanish (es)
Inventor
Karl Ægir Karlsson
Haraldur Þorsteinsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3Z ehf
Original Assignee
3Z ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2101291.9A external-priority patent/GB202101291D0/en
Priority claimed from GBGB2101296.8A external-priority patent/GB202101296D0/en
Priority claimed from GBGB2101292.7A external-priority patent/GB202101292D0/en
Application filed by 3Z ehf filed Critical 3Z ehf
Application granted granted Critical
Publication of ES3038949T3 publication Critical patent/ES3038949T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES22708379T 2021-01-29 2022-01-28 Compounds for use in the treatment of attention deficit hyperactivity disorder Active ES3038949T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2101291.9A GB202101291D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101296.8A GB202101296D0 (en) 2021-01-29 2021-01-29 Novel treatments
GBGB2101292.7A GB202101292D0 (en) 2021-01-29 2021-01-29 Novel treatments
PCT/EP2022/052142 WO2022162199A2 (en) 2021-01-29 2022-01-28 Novel treatments

Publications (1)

Publication Number Publication Date
ES3038949T3 true ES3038949T3 (en) 2025-10-16

Family

ID=80682355

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22708379T Active ES3038949T3 (en) 2021-01-29 2022-01-28 Compounds for use in the treatment of attention deficit hyperactivity disorder

Country Status (12)

Country Link
US (2) US20240130995A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284356B1 (cg-RX-API-DMAC7.html)
JP (1) JP7891230B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022215118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206935A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038949T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250747T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071725T2 (cg-RX-API-DMAC7.html)
PL (1) PL4284356T3 (cg-RX-API-DMAC7.html)
RS (1) RS66934B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500238T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022162199A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093748A1 (en) * 2023-11-03 2025-05-08 3Z Pharmaceuticals Use of a calcium channel blocker in the treatment of adhd

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1030672A1 (en) * 1997-11-19 2000-08-30 Merck & Co., Inc. Method for treating attention deficit disorder
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2004292966A1 (en) 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
US9408837B2 (en) 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
WO2014041035A1 (en) 2012-09-11 2014-03-20 Institució Catalana De Recerca I Estudis Avançats Diagnostic method for detecting an autoimmune disease and related subject-matter
WO2014133329A1 (ko) * 2013-02-27 2014-09-04 에스케이케미칼 주식회사 관절염 치료용 복합 제제
KR20140135676A (ko) * 2014-10-02 2014-11-26 한국과학기술원 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 t―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물
BR112020008371A2 (pt) * 2017-10-27 2020-11-03 Esteve Pharmaceuticals, S.A. novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor
WO2020120606A1 (en) * 2018-12-12 2020-06-18 Esteve Pharmaceuticals, S.A. New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions

Also Published As

Publication number Publication date
EP4284356B1 (en) 2025-04-02
JP7891230B2 (ja) 2026-07-16
WO2022162199A2 (en) 2022-08-04
JP2024508372A (ja) 2024-02-27
US20240130995A1 (en) 2024-04-25
CA3206935A1 (en) 2022-08-04
EP4284356A2 (en) 2023-12-06
HRP20250747T1 (hr) 2025-08-15
WO2022162199A3 (en) 2022-09-15
HUE071725T2 (hu) 2025-09-28
RS66934B1 (sr) 2025-07-31
EP4284356C0 (en) 2025-04-02
AU2022215118A1 (en) 2023-08-17
AU2022215118A9 (en) 2024-05-16
SMT202500238T1 (it) 2025-07-22
PL4284356T3 (pl) 2025-07-28
US20260199279A1 (en) 2026-07-16

Similar Documents

Publication Publication Date Title
ES2930628T3 (es) Uso de pridopidina para mejorar la memoria
ES2992838T3 (en) Treatment of irritability in autism spectrum disorder with cannabidiol
ES2638074T3 (es) Carbamatos para utilizar en el síndrome de piernas inquietas
ES2164040T3 (es) Uso de d-serina o de d-alanina para el tratamiento de la esquizofrenia.
US8383681B2 (en) Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
JP5836280B2 (ja) 注意欠陥/多動性障害(adhd)の治療方法
JP5901528B2 (ja) 線維筋痛症候群の治療方法
WO2005055951A2 (en) Methods and compositions for slowing aging
US20170304351A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
ES2881081T3 (es) Procedimientos y composiciones para mejorar la función cognitiva
ES2983441T3 (es) Acetil-leucina para su uso en el tratamiento de síndrome de las piernas inquietas
ES2847169T3 (es) Tratamiento de migraña con acetil-leucina
ES2237842T3 (es) Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad.
ES2661835T3 (es) Enantiómero (R) de la lauflumida a más del 95%ee
EP4284356B1 (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
CN119212690A (zh) 包含meai和n-酰基乙醇胺的组合物及其用途
US20240002369A1 (en) Novel treatments of attention deficit/hyperactivity disorder
CN116981460A (zh) 注意力缺陷/多动障碍的新颖治疗
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
HK40101538B (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
HK40101538A (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
WO2025093748A1 (en) Use of a calcium channel blocker in the treatment of adhd
WO2023084054A1 (en) Treatment of adhd using selective binders of the 11-imidazoline receptor
ES2326355B1 (es) Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
CN117120046A (zh) 用于治疗注意力缺陷多动障碍的化合物